Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pozzilli, Paolo
CONSERVA, NCT05368402 / 2022-000743-68: Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.	Terminated	2	3	Europe	Ladarixin, LDX, Placebo	Dompé Farmaceutici S.p.A, Dompé farmaceutici S.P.A.	Type 1 Diabetes	09/23	09/23
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function	Active, not recruiting	2	140	Europe, US, RoW	Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo	Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.	Recent Onset type1 Diabetes	04/24	04/26
Zazzo, Antonio Di
No trials found